| Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 1956 | 2020 |
| Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma FL Locke, DB Miklos, CA Jacobson, MA Perales, MJ Kersten, OO Oluwole, ... New England Journal of Medicine 386 (7), 640-654, 2022 | 1180 | 2022 |
| Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium LJ Nastoupil, MD Jain, L Feng, JY Spiegel, A Ghobadi, YI Lin, S Dahiya, ... Journal of Clinical Oncology 38 (27), 3119-3128, 2020 | 713 | 2020 |
| Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma AJ Sim, MD Jain, NB Figura, JC Chavez, BD Shah, F Khimani, A Lazaryan, ... International Journal of Radiation Oncology* Biology* Physics 105 (5), 1012-1021, 2019 | 155 | 2019 |
| Axicabtagene ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory large B-cell lymphoma: real world experience LJ Nastoupil, MD Jain, JY Spiegel, A Ghobadi, Y Lin, S Dahiya, ... Blood, The Journal of the American Society of Hematology 132 (Supplement 1 …, 2018 | 132 | 2018 |
| Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi … MJ Frank, NM Hossain, A Bukhari, E Dean, JY Spiegel, GK Claire, I Kirsch, ... Journal of Clinical Oncology 39 (27), 3034-3043, 2021 | 126 | 2021 |
| Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy JY Spiegel, S Dahiya, MD Jain, J Tamaresis, LJ Nastoupil, MT Jacobs, ... Blood, The Journal of the American Society of Hematology 137 (13), 1832-1835, 2021 | 122 | 2021 |
| Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium Y Wang, P Jain, FL Locke, MJ Maurer, MJ Frank, JL Munoz, S Dahiya, ... Journal of clinical oncology 41 (14), 2594-2606, 2023 | 115 | 2023 |
| Immune effector cell–associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes NG Holtzman, H Xie, S Bentzen, V Kesari, A Bukhari, F El Chaer, F Lutfi, ... Neuro-oncology 23 (1), 112-121, 2021 | 82 | 2021 |
| Treatment of cerebral radiation necrosis with bevacizumab: the Cleveland clinic experience NH Sadraei, S Dahiya, ST Chao, ES Murphy, K Osei-Boateng, H Xie, ... American journal of clinical oncology 38 (3), 304-310, 2015 | 82 | 2015 |
| Sleep disturbances in cancer patients: underrecognized and undertreated S Dahiya, MS Ahluwalia, HK Walia Cleve Clin J Med 80 (11), 722-732, 2013 | 76 | 2013 |
| Role of immunotherapy in Ewing sarcoma E Morales, M Olson, F Iglesias, S Dahiya, T Luetkens, D Atanackovic Journal for ImmunoTherapy of Cancer 8 (2), e000653, 2020 | 70 | 2020 |
| Experience with axicabtagene ciloleucel (Axi-cel) in patients with secondary CNS involvement: results from the US lymphoma CAR T consortium NN Bennani, MJ Maurer, LJ Nastoupil, MD Jain, JC Chavez, AF Cashen, ... Blood 134, 763, 2019 | 67 | 2019 |
| Risk of second tumors and T-cell lymphoma after CAR T-cell therapy MP Hamilton, T Sugio, T Noordenbos, S Shi, PL Bulterys, CL Liu, X Kang, ... New England Journal of Medicine 390 (22), 2047-2060, 2024 | 66 | 2024 |
| Characteristics and outcomes of patients receiving bridging therapy while awaiting manufacture of standard of care axicabtagene ciloleucel CD19 chimeric antigen receptor (CAR … MD Jain, MT Jacobs, LJ Nastoupil, JY Spiegel, G Feng, Y Lin, ... Blood 134, 245, 2019 | 60 | 2019 |
| Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma M Elsawy, JC Chavez, I Avivi, JF Larouche, L Wannesson, K Cwynarski, ... Blood, The Journal of the American Society of Hematology 140 (21), 2248-2260, 2022 | 43 | 2022 |
| Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy NM Hossain, S Dahiya, R Le, AM Abramian, KA Kong, LS Muffly, ... Leukemia & lymphoma 60 (2), 503-506, 2019 | 39 | 2019 |
| Continuing challenges and current issues in acute lymphoblastic leukemia A Kansagra, S Dahiya, M Litzow Leukemia & Lymphoma 59 (3), 526-541, 2018 | 39 | 2018 |
| Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study F Morschhauser, S Dahiya, ML Palomba, A Martin Garcia-Sancho, ... Nature medicine 30 (8), 2199-2207, 2024 | 37 | 2024 |
| Length of stay and hospital costs for patients undergoing allogeneic stem-cell transplantation A Godara, NS Siddiqui, S Munigala, R Dhawan, AJ Kansagra, ... JCO oncology practice 17 (3), e355-e368, 2021 | 34 | 2021 |